Insider trade

Director sold ~$567K of PBYI shares in the open market

Traded Sep 14, 2026 · Filed Sep 17, 2026

Why it stands out

A board member of Puma Biotechnology sold $567K of Puma Biotechnology shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Director$500K–$1MPre-arranged plan referenced

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$566,994

Shares × reported transaction price

Timing vs results

39 days after results of Aug 6, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Adoption date of referenced 10b5-1(c) plan is: 06-15-2026
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.03 to $9.2, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

Scheduled in advance3w ago

3w ago

Derivative exercise or conversion — not an open-market buy.

3w ago

Derivative exercise or conversion — not an open-market buy.